CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Analysts Are Bullish on Top Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Kura Oncology (KURA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zimmer Biomet Holdings (ZBH – Research Report), ...
Cystic fibrosis drug developer Sionna rises on trading debut
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...
Hosted on MSN14h
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...
BioSpace18h
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
US close: Stocks sink as trade war concerns intensify
US stocks fell sharply on Friday as investors digested a mixed January employment report amid an escalation of concerns about a trade war following comments from Donald Trump.